Harvard Medical School

kymriah

Pharma

Novartis' Kymriah should cost $160,000, new analysis contends

A new analysis suggests Novartis could make a decent profit on Kymriah if the cost was just one-third its current price of $475,000.

Eric Sagonowsky Feb 8, 2018 12:33pm

HIV

'Mosaic' HIV vaccine from J&J and partners passes early test

Jul 24, 2017 4:00am